People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Taligen Therapeutics Inc | — | Biotechnology | Series B | $62.1M | $1.4B | 2008 |
| Calistoga Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $60.3M | $850.1M | 2009 |
| Sunesis Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $38.5M | $969.1M | 2009 |
| Arialys Therapeutics, Inc. | — | Biotechnology | Series A | $29.1M | $49.2M | 2022 |
| ViewPoint Therapeutics, Inc. | — | Biotechnology | Series B | $24.9M | $830.9M | 2016 |
| Macrogenics Inc | — | Biotechnology | Series A | $12.0M | $434.4M | 2011 |
| BioIntervene, Inc. | — | Pharmaceuticals | Series A | $8.8M | $115.0M | 2021 |
| Cara Therapeutics, Inc. | — | Biotechnology | Series A | $4.9M | $3.6M | 2010 |
| Rekindle Therapeutics Inc. | — | Biotechnology | Seed | $1.1M | $48.8M | 2018 |
Ed Hurwitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ed Hurwitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.